Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC.

9090Background: The SWOG 0819 study compared chemotherapy (CT) (+/- bevacizumab) to CT combined with cetuximab and included 1,313 eligible patients (pts) of which 321 had squamous histology (SCC). ...